Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Shares Outstanding (Diluted Average) (2020 - 2025)

vTv Therapeutics (VTVT) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 45.96% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, up 45.96% year-over-year, with the annual reading at $8.4 million for FY2025, 45.96% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $8.4 million in Q4 2025 for vTv Therapeutics, up from $7.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $80.5 million in Q3 2022 to a low of $1.6 million in Q4 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $20.9 million across 5 years, with a median of $6.4 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 97.41% in 2023 and later soared 207.12% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $1.6 million in 2021, then rose by 22.58% to $1.9 million in 2022, then increased by 8.6% to $2.1 million in 2023, then soared by 176.79% to $5.8 million in 2024, then skyrocketed by 45.96% to $8.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for VTVT at $8.4 million in Q4 2025, $7.1 million in Q3 2025, and $6.6 million in Q2 2025.